Noah Levit
0000-0002-0797-5121
6 papers found
Refreshing results…
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis
Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis
Laboratory Safety of Dupilumab in Patients Aged 6–11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial
Missing publications? Search for publications with a matching author name.